Connect
MJA
MJA

Is the end of chronic hepatitis C virus infection in sight?

Geoffrey W McCaughan
Med J Aust 2012; 196 (10): 614. || doi: 10.5694/mja12.10586
Published online: 4 June 2012

Direct antiviral agents may hold the key to eradication, but only if they reach those who will benefit

In this issue of the Journal, Dore outlines the astonishing recent progress in the treatment of hepatitis C virus (HCV) infection,1 largely triggered by the approval in 2011 by regulatory bodies, both overseas and in Australia, of the first two direct antiviral agents (DAAs) against HCV. These two agents, telaprevir and boceprevir, only target genotype 1 HCV and are used in combination with the current standard of care — pegylated interferon and ribavirin. This triple-therapy combination represents two main advances: an increase in sustained virological response (SVR) from 45% to 70%, and a shortened duration of treatment from 12 to 6 months in about 50% of patients. However, these benefits come with an increased side-effect profile compared with the current standard of care. In fact, the results from the current standard of care in Australia are also published in this issue of the Journal and reflect world’s best practice in treating patients with HCV infection.2

  • Geoffrey W McCaughan1,2

  • 1 Liver Immunobiology Program, Centenary Research Institute, Sydney, NSW.
  • 2 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW.


Competing interests:

I am a member of the Gilead, Janssen-Cilag, and Merck Sharp and Dohme advisory boards, and have received consultancy payments from these companies.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.